Abstract
621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have